Evidence map›Paper›PMID 41244135›Full record

ArticleAmerican journal of cancer research2025

Serum biomarker changes in pulmonary fibrosis with lung cancer and their correlation with patient survival prognosis.

Chaofeng Liu, Zhenyu Xiang, Xiaoyan Wang, Xiaojuan Liu, Mingxia Hou, Sijin Li

Abstract read
In one paragraph

Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chaofeng LiuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University Taiyuan, Shanxi, China.
Zhenyu XiangCollaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University Taiyuan, Shanxi, China.
Xiaoyan WangDepartment of Intensive Care Unit, The First People's Hospital of Zhengzhou Zhengzhou, Henan, China.
Xiaojuan LiuNational Health Commission Key Laboratory of Pneumoconiosis Taiyuan, Shanxi, China.
Mingxia HouNational Health Commission Key Laboratory of Pneumoconiosis Taiyuan, Shanxi, China.
Sijin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University Taiyuan, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to characterize serum tumor markers - cytokeratin 19 fragment (Cyfra21-1), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE), and squamous cell carcinoma antigen (SCC) - together with arterial blood gas and pulmonary function parameters (partial pressure of oxygen [PO

Indexed as

competing risk modeldiagnostic performancelung cancerprognosisPulmonary fibrosispulmonary functionserum tumor markers

Identifiers

PMID41244135
PMCPMC12616167

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.